Under a tenth of patients who could benefit from obesity jabs including Wegovy can access them, warns the World Health Organization as it issues its initial advice on the medications.
Given in excess of 1,000,000,000 individuals worldwide now classified as obese, it is advocating for increased and just access to this class of drugs.
Per projections, in excess of 2,000,000,000 could be obese by 2030 without intervention.
"The new guidance affirms that obesity is a lifelong illness that can be addressed with comprehensive and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are key barriers to widespread availability to the treatments that can assist patients in reducing considerable body mass, notes the body.
GLP-1 Therapy Scarcity
Even under the present best projected scenario, the production of such drugs would only suffice for approximately 100 million people – fewer than 10% of the global need, as stated by the WHO.
The guideline calls on countries and companies to expand access, via strategies including licensing agreements.
The intellectual property rights on the active ingredient – the core ingredient of a leading brand – is scheduled to end in multiple countries in 2026.
The Way Weight-Loss Drugs Operate
The injections mimick a biological compound to delay gastric emptying, suppress the appetite and enhance feelings of fullness so people eat less.
Patients typically see weight reduction within a few weeks of commencing the weekly injections.
Studies points to users may see weight return within a year of halting the treatment, because their normal appetite come back.
Being above a healthy weight increases your risk for contracting medical conditions, such as type 2 diabetes, cardiovascular issues, stroke, and certain malignancies.
Obesity affects people in every country and was responsible for 3.7 million fatalities worldwide in 2024, as per the health agency.
